Phase I study to assess safety and tolerability of investigative medication in pediatric patients with Sanfilippo syndrome (MPS IIIA)

A specialty healthcare company developing treatments for rare diseases sought Raremark’s support for an early-stage pediatric trial program testing an investigational medicine in Sanfilippo syndrome. Raremark was commissioned to run a nine-month online campaign to raise the profile of the program and to find and refer up to four of the nine patients needed for the Phase I study in the United States; to a study site that initially had no patients of their own.

We found, prescreened and referred three eligible children and their parents within three weeks of study start-up.

Download the Xperiome case study Phase I study to assess safety and tolerability of investigative medication in pediatric patients with Sanfilippo syndrome (MPS IIIA).

Get in touch

Interested in working with us? we’d love to hear from you. Please use the form below to provide us with a few details and we’ll get back in touch with you.


All fields required
Maximum 300 characters

United States office

Five Cowboys Way

Suite 300

Frisco TX 75034

+1 972-382-7227

United Kingdom office

Kemp House

152-160 City Road

London EC1V 2NX

+44 20 3920 9880